Yun M. Shim, MD
Dr. Yun Michael Shim is the director of Pulmonary Rehabilitation and the director of the Pulmonary Function Testing lab at UVA Health in Charlottesville, Virginia. He is also a member of both the Lung Cancer team and the Mesothelioma team at UVA Comprehensive Cancer Center, where he is one of several experts working together to make a plan for patients diagnosed with these challenging diseases. The lung cancer and mesothelioma teams include specialists in cancer, lung care, radiology, and surgery. The treatment they provide is grounded in research, including that conducted by Dr. Shim’s lab.[1]
Dr. Shim also diagnoses and treats patients with respiratory diseases such as asthma, cystic fibrosis, and allergies.
Education and Career
Dr. Shim attended medical school at the Medical College of Virginia/Virginia Commonwealth University. He completed his internship and residency in Internal Medicine at Northwestern University, then pursued a post-doctoral fellowship in Pulmonary Disease and Critical Care Medicine at Yale University, where he also completed an additional fellowship in Advanced Asthma and Obstructive Airway Disease. He is board-certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine.[1]
Professional Memberships
Dr. Shim is a fellow of the American College of Chest Physicians, and a member of the American Thoracic Society, the American College of Physicians, and the Society of Hospital Medicine.[1]
Research
Dr. Shim heads his own laboratory within the Division of Pulmonary & Critical Care Medicine at the University of Virginia School of Medicine. The Y. Michael Shim Lab’s research areas include therapeutics and drug discovery; in vivo lung imaging using hyperpolarized gas MRI; obstructive lung diseases; the role of obesity and exercise in the pathogenesis of asthma; the role of exercise and COPD outcomes; and lung cancer.[2]
Funded projects include:[2]
- NIH/ULTR003015 (Health Effects of JUUL in Healthy Young Electronic Cigarette Users)
- NIH/NHLBI 1R01HL (Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics)
- DOD W0259_18_WR (A dual approach to combating infection by targeting the host’s inflammatory response and bacterial pathogens)
- NIH/NHLBI 1R43HL147667 (Respiratory Oxygen Adherence Monitor for COPD patient)
- Genentech (129Xe MRI assessment of disease progression in patients with COPD treated with standard-of-care medications with or without daily open-label azithromycin treatment to prevent acute exacerbation)
